Videos

CheckMate-9ER Shows Efficacy of Nivolumab/Cabozantinib Combo in RCC

September 25, 2020

Bradley McGregor, MD, discusses the CheckMate-9ER trial of nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Exploring Targeted and CAR T-Cell Therapies on the Horizon for MCL

September 25, 2020

Michael Wang, MD, discusses potential upcoming treatment options for patients with mantle cell lymphoma, including targeted therapies and chimeric antigen receptor T cells.

A 73-Year-Old Woman With Differentiated Thyroid Cancer

September 25, 2020

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.

A 77-Year-Old Woman with DLBCL

September 25, 2020

John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.

ACCC President Highlights Oncology Community Response to COVID-19 Pandemic

September 24, 2020

Randall A. Oyer, MD, discusses the importance of the ACCC community during the unprecedented coronavirus disease 2019 pandemic.

Targeting CD19 in Diffuse Large B-Cell Lymphoma: Treatment Updates

September 24, 2020

A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.

Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer

September 23, 2020

Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma

September 23, 2020

Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.

Tafasitamab Plus Lenalidomide Approval Generates Excitement for Second-Line DLBCL

September 22, 2020

Kami J. Maddocks, MD, discusses the role of tafasitamab and lenalidomide following the approval of this agent as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

A 58-Year-Old Man With Advanced Renal Cell Carcinoma

September 22, 2020

Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.